Drug for overactive bladder could be made available over counter for first time
Women with the condition are being urged to take part in a consultation on whether to make a treatment available without prescription.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Millions of women suffering from an overactive bladder have been urged to take part in a consultation that could make a treatment available over the counter for the first time.
The call for evidence, launched on Saturday, could lead to the medicine Aquiette being reclassified so that it can be obtained at a pharmacy without a prescription.
It is estimated that around one in six women in the UK have symptoms associated with overactive bladder, such as the sudden, uncontrolled need to urinate which can lead to accidental leaks.
Aquiette tablets are used to treat women with milder symptoms of the condition which cannot be controlled by bladder training alone.
For many women, an overactive bladder can make day-to-day living extremely challenging
The Medicines and Healthcare products Regulatory Agency (MHRA) is calling on people with the condition, as well as healthcare professionals with experience of treating it, to share their views in the reclassification consultation.
Dr Laura Squire, chief healthcare quality and access officer at the MHRA, said: “For many women, an overactive bladder can make day-to-day living extremely challenging.
“It can impact on relationships, on work, on social life, and it can lead to anxiety and depression.
“Fortunately there are treatments around, and from today you will have a chance to have your say on whether one of those treatments, Aquiette, can be available for the first time without a prescription.”
Minister for women’s health Maria Caulfield said: “When it comes to sensitive issues such as bladder control, speaking to a GP may act as a barrier for some women to seek help.
“Reclassification of Aquiette would enable women to access vital medication without needing a prescription.”